Capecitabine + Epirubicin + Cyclophosphamide Combination Therapy (CEX Therapy) as Neoadjuvant Chemotherapy for HER-2-Negative Breast Cancer: A Retrospective, Single-Center Study-Reference-Cited by-同舟云学术

Capecitabine + Epirubicin + Cyclophosphamide Combination Therapy (CEX Therapy) as Neoadjuvant Chemotherapy for HER-2-Negative Breast Cancer: A Retrospective, Single-Center Study

Published:2020-04-15 Issue:2 Volume:87 Page:73-79
ISSN:1345-4676
Container-title:Journal of Nippon Medical School
language:en
Short-container-title:J Nippon Med Sch

Author:

Yokoyama Tadashi¹,Makino Hiroshi¹,Seki Natsuki¹,Ueda Junji¹,Hosone Masaru²,Katayama Hironori²,Takei Hiroyuki³,Yoshida Hiroshi⁴

Affiliation:

1. Department of Surgery, Nippon Medical School Tama Nagayama Hospital

2. Department of Pathology, Nippon Medical School Tama Nagayama Hospital

3. Department of Breast Surgical Oncology, Nippon Medical School

4. Department of Gastroenterological Surgery, Nippon Medical School

Publisher

Medical Association of Nippon Medical School

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jnms/87/2/87_JNMS.2020_87-204/_pdf

Reference40 articles.

1. 1. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24 (13):2019-27.

2. 2. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23 (16):3676-85.

3. 3. Caudle AS, Gonzalez-Angulo AM, Hunt KK, et al. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28 (11):1821-8.

4. 4. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384 (9938):164-72.

5. 5. de Azambuja E, Holmes AP, Piccart-Gebhart M. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014;15 (10):1137-46.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic effects of ozone with doxorubicin on the proliferation, apoptosis and metastatic profile of luminal-B type human breast cancer cell line;Tissue and Cell;2023-12

2. Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer;Biologics: Targets and Therapy;2023-09